A compound of Formula I, which includes pharmaceutically acceptable salts thereof, ** Formula ** in which: Z is Q is selected from the group consisting of: -W- is R1, R2, R3, R4 and R5, is independently selected from the group consisting of hydrogen, halogen, cyano, nitro, COOR8, XR9 and B； m is 2； R6 is O or does not exist； R7 is (CH2) nR10； n is 0-6； R10 is selected from the group consisting of H, (C1-6) alkyl, -C (O) -alkyl (C1-6), C (O) -phenyl and CONR11R12； R11 and R12 are each independently H, (C1-6) alkyl or phenyl； - - represents a carbon-carbon bond or does not exist； D is selected from the group consisting of hydrogen, (C1-6) alkyl, (C2-6) alkynyl, cycloalkyl (C3-6), halogen, cyano, -CONR32R33, -SO2R32, COR32, COOR8, tetrahydrofuryl, pyrrolidinyl, phenyl and heteroaryl； wherein said (C1-6) alkyl, (C2-6) alkynyl, phenyl and heteroaryl independently are each optionally substituted with one to three equal or different members selected from the group G； heteroaryl is selected from the group consisting of furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, tetrazolyl, triazolyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl；Un compuesto de Fórmula I, que incluye sales farmacéuticamente aceptables del mismo,**Fórmula** en la que: Z es Q se selecciona entre el grupo que consiste en: -W- es R1, R2, R3, R4 y R5, se seleccionan independientemente entre el grupo que consiste en hidrógeno, halógeno, ciano, nitro, COOR8, XR9 y B； m es 2； R6 es O o no existe； R7 es (CH2)nR10； n es 0-6； R10 se selecciona entre el grupo que consiste en H, alquilo (C1-6), -C(O)-alquilo (C1-6), C(O)-fenilo y CONR11R12； R11 y R12 son cada uno independientemente H, alquilo (C1-6) o fenilo； - - representa un enlace carbono-carbono o no existe； D se selecciona entre el grupo que consiste en hidrógeno, alquilo (C1-6), alquinilo (C2-6), cicloalquilo (C3-6), halógeno, ciano, -CONR32R33, -SO2R32, COR32, COOR8, tetrahidrofurilo, pir
